Elafibranor Monoxide Impurity

The Elafibranor Monoxide impurity, known as (E)-2-(2,6-dimethyl-4-(3-(4-(methylsulfinyl)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic acid, is an important pharmaceutical impurity found during the synthesis of Elafibranor. It has a molecular formula of C22H24O5S and a molecular weight of 400.49 g/mol. Monitoring this impurity is crucial for quality control and ensuring the safety and effectiveness of the final drug product. Proper identification and analysis of this Elafibranor-related impurity help manufacturers meet regulatory standards and produce a high-purity pharmaceutical compound.

Manasa Life Sciences manufactures and supplies high-quality pharmaceutical impurities from Hyderabad, India, serving markets across Asia, Europe, Africa, the GCC, and the UAE. We ensure reliable global delivery, complete traceability, and strict adherence to Good Documentation Practices (GDP) for all impurity standards and reference materials.

We support comprehensive impurity-control readiness by providing certified impurity reference standards, performing detailed risk assessments, and developing and validating highly sensitive LC-MS/MS and GC-MS analytical methods. Our solutions enable accurate detection, identification, quantification, and control of impurities, including process-related, synthesis-related, degradation-related, and trace-level impurities. This helps pharmaceutical manufacturers meet USP and other global regulatory requirements, maintain full compliance, and ensure the highest standards of product quality and patient safety.